AARD AARDVARK THERAPEUTICS INC revenue, earnings and financials
For the quarter ended June 30, 2026, AARDVARK THERAPEUTICS INC reported revenue of n/a, net income of −$14.4M and diluted EPS of −$0.66; for the fiscal year ended December 2025 revenue was $0.
AARD annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $0, gross profit n/a, operating income −$62.7M, net income −$57.6M (margin n/a), EPS −$2.93
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$22.8M, net income −$20.6M (margin n/a), EPS −$5.15
AARD quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$14.4M, EPS −$0.66
- Quarter ended Mar 31, 2026: revenue $0, net income −$21.6M, EPS −$0.99
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$17.6M, EPS −$0.81
- Quarter ended Sep 30, 2025: revenue n/a, net income −$16.3M, EPS −$0.75
- Quarter ended Jun 30, 2025: revenue n/a, net income −$14.4M, EPS −$0.66
- Quarter ended Mar 31, 2025: revenue $0, net income −$9.31M, EPS −$0.71
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$8.78M, EPS −$2.18
- Quarter ended Sep 30, 2024: revenue n/a, net income −$4.18M, EPS −$1.05
- Quarter ended Jun 30, 2024: revenue n/a, net income −$5.45M, EPS −$1.37
- Quarter ended Mar 31, 2024: revenue n/a, net income −$2.18M, EPS −$0.55
AARD cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$54.2M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$18.1M, share buybacks n/a
AARD balance sheet
- Jun 30, 2026: cash $73.8M, total assets $81.5M, total liabilities $6.66M, shareholders' equity $74.8M
- Mar 31, 2026: cash $62.4M, total assets $98.6M, total liabilities $11.6M, shareholders' equity $87.0M
- Dec 31, 2025: cash $47.1M, total assets $117M, total liabilities $10.5M, shareholders' equity $107M
- Sep 30, 2025: cash $39.3M, total assets $133M, total liabilities $10.9M, shareholders' equity $122M
- Jun 30, 2025: cash $26.0M, total assets $147M, total liabilities $10.6M, shareholders' equity $137M
- Mar 31, 2025: cash $26.5M, total assets $157M, total liabilities $6.34M, shareholders' equity $151M
- Dec 31, 2024: cash $61.6M, total assets $77.5M, total liabilities $5.39M, shareholders' equity −$54.6M
What is AARD's revenue?
AARDVARK THERAPEUTICS INC reported $0 of revenue for the fiscal year ended December 2025.
Is AARD profitable?
No. AARDVARK THERAPEUTICS INC lost $69.9M over the last four quarters.
What is AARD's EPS?
Diluted earnings per share over the last four quarters were −$3.21; −$0.66 in the latest quarter.